Eyenovia (NASDAQ:EYEN) Upgraded at ValuEngine

ValuEngine upgraded shares of Eyenovia (NASDAQ:EYEN) from a hold rating to a buy rating in a report released on Friday morning, ValuEngine reports.

Separately, Zacks Investment Research upgraded Eyenovia from a hold rating to a buy rating and set a $3.75 target price on the stock in a research report on Friday, August 16th.

EYEN opened at $3.29 on Friday. Eyenovia has a 52 week low of $2.40 and a 52 week high of $6.98. The business’s fifty day simple moving average is $3.75 and its 200 day simple moving average is $4.47.

Eyenovia (NASDAQ:EYEN) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.03. Equities analysts predict that Eyenovia will post -1.69 earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Eyenovia stock. Uniplan Investment Counsel Inc. increased its holdings in shares of Eyenovia Inc (NASDAQ:EYEN) by 22.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 544,896 shares of the company’s stock after buying an additional 99,896 shares during the quarter. Uniplan Investment Counsel Inc. owned about 3.31% of Eyenovia worth $2,343,000 as of its most recent filing with the Securities and Exchange Commission. 8.90% of the stock is owned by institutional investors.

About Eyenovia

Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.

Recommended Story: How Investors Can Profit from Options Trading

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.